Efficacy Study of Oral Seliciclib to Treat Non-Small Cell Lung Cancer

Inclusion Criteria:

Adult patients with histologically-confirmed recurrent non-small cell lung cancer have had at least two prior systemic treatment regimens
Must have measurable disease according to RECIST
Eastern Cooperative Oncology Group performance status 0-1
Adequate bone marrow, hepatic and renal function
Ability to swallow capsules
At least 3 weeks from prior systemic treatments including investigational anti-cancer therapy, at least 7 days from prior radiation therapy and have recovered from prior toxicities
At least 3 weeks from major surgery

Exclusion Criteria:

Non-small cell cancer histology contains a component of small cell lung cancer
Previously untreated CNS metastasis or progressive CNS metastasis
Prior treatment with a CDK inhibitor
Currently receiving radiotherapy, biological therapy, or any other investigational therapy
Uncontrolled intercurrent illness
Having other cancers that have been treated with chemotherapy or biological therapy in the past 5 years with the exception of adequately treated in situ cervical cancer or basal cell skin cancer
Pregnant or lactating women
Known to be HIV-positive
Active hepatitis B and/or hepatitis C infection